Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia

British Journal of Haematology

Volumn 174, Issue 4, 2016, Pages 526-535

  Cressman, Sonya ^a,b   Karsan, Aly ^c,d,e   Hogge, Donna E ^b,e,f   McPherson, Emily ^a,b   Bolbocean, Corneliu ^a,b,e   Regier, Dean A ^a,b,e   Peacock, Stuart J ^a,b,g  

^a Canadian Centre for Applied Research in Cancer Control ARCC   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c CANADA'S MICHAEL SMITH GENOME SCIENCES CENTRE   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

^g SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Cost effectiveness; first remission treatment; genomic analysis; intermediate risk AML

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANADA; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; GENETIC ANALYSIS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INTERMEDIATE RISK POPULATION; LONG TERM SURVIVAL; MATHEMATICAL MODEL; MIDDLE AGED; MOLECULAR DIAGNOSIS; MORTALITY RATE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SIMULATION;

EID: 84982883782     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14076     Document Type: Article

References (39)

1. Ashfaq, K., Yahaya, I., Hyde, C., Andronis, L., Barton, P., Bayliss, S. & Chen, Y. F. (2010). Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technology Assessment, 14, iii-iv, ix-xi, 1–141.
2. Barr, R.D. (2012) Economic evaluation of hematopoietic stem cell transplantation. Hematology, 17, S198–201.
3. Boissel, N., Nibourel, O., Renneville, A., Gardin, C., Reman, O., Contentin, N., Bordessoule, D., Pautas, C., de Revel, T., Quesnel, B., Huchette, P., Philippe, N., Geffroy, S., Terre, C., Thomas, X., Castaigne, S., Dombret, H. & Preudhomme, C. (2010) Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. Journal of Clinical Oncology, 28, 3717–23.
4. Cagnetta, A., Adamia, S., Acharya, C., Patrone, F., Miglino, M., Nencioni, A., Gobbi, M. & Cea, M. (2014) Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. Leukemia Research, 38, 649–659.
5. Caligiuri, M.A., Strout, M.P., Lawrence, D., Arthur, D.C., Baer, M.R., Yu, F., Knuutila, S., Mrozek, K., Oberkircher, A.R., Marcucci, G., de la Chapelle, A., Elonen, E., Block, A.W., Rao, P.N., Herzig, G.P., Powell, B.L., Ruutu, T., Schiffer, C.A. & Bloomfield, C.D. (1998) Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Research, 58, 55–9.
6. Cancer Genome Atlas Research Network (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New England Journal of Medicine, 368, 2059–74.
7. Chaturvedi, A., Araujo CRUZ, M. M., Jyotsana, N., Sharma, A., Yun, H., Gorlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., Meyer, J., Haemmerle, R., Struys, E. A, Jansen, E. E, Modlich, U., LI, Z, Sly, L. M., Geffers, R., Lindner, R., Manstein, D. J., Lehmann, U., Krauter, J., Ganser, A. & Heuser, M. (2013) Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 122, 2877–87.
8. Dohner, K., Tobis, K., Ulrich, R., Frohling, S., Benner, A., Schlenk, R.F. & Dohner, H. (2002) Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. Journal of Clinical Oncology, 20, 3254–61.
9. Dohner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rucker, F.G., Corbacioglu, A., Bullinger, L., Frohling, S. & Dohner, H. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740–6.
10. Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Lowenberg, B. & Bloomfield, C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453–74.
11. Drummond, M., Sculpher, M., Torrance, G., O'Brien, B. & Stoddart, G. (2005) Methods for the economic evaluation of health care programmes, 3rd edn. University Press Oxford, Oxford.
12. Estey, E.H. (2014) Acute myeloid leukemia: 2014 Update on risk-stratification and management. American Journal of Hematology, 89, 1063–81.
13. Fey, M.F. & Buske, C. 2013. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24 vi138–43.
14. Gale, R.E., Green, C., Allen, C., Mead, A.J., Burnett, A.K., Hills, R.K., Linch, D.C. & Medical Research Council Adult Leukaemia Working Party (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 111, 2776–84.
15. Green, C.L., Evans, C.M., Zhao, L., Hills, R.K., Burnett, A.K., Linch, D.C. & Gale, R.E. (2011) The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood, 118, 409–12.
16. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood, 116, 354–65.
17. Johnson, D. E. & Redner, R. L. 2015. An ATRActive future for differentiation therapy in AML. Blood Reviews, 4, 263–8.
18. Koreth, J., Schlenk, R., Kopecky, K.J., Honda, S., Sierra, J., Djulbegovic, B.J., Wadleigh, M., Deangelo, D.J., Stone, R.M., Sakamaki, H., Appelbaum, F.R., Dohner, H., Antin, J.H., Soiffer, R.J. & Cutler, C. (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA, 301, 2349–61.
19. Kurosawa, S., Yamaguchi, T., Miyawaki, S., Uchida, N., Kanamori, H., Usuki, K., Yamashita, T., Watanabe, M., Yakushiji, K., Yano, S., Nawa, Y., Taguchi, J., Takeuchi, J., Tomiyama, J., Nakamura, Y., Miura, I., Kanda, Y., Takaue, Y. & Fukuda, T. (2011) A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood, 117, 2113–20.
20. Leunis, A., Blommestein, H.M., Huijgens, P.C., Blijlevens, N.M., Jongen-Lavrencic, M. & Uly-de-Groot, C.A. (2013a) The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leukemia Research, 37, 245–50.
21. Leunis, A., Redekop, W.K., van Montfort, K.A., Lowenberg, B. & Uly-de-Groot, C.A. (2013b) The development and validation of a decision-analytic model representing the full disease course of acute myeloid leukemia. Pharmacoeconomics, 31, 605–21.
22. Levy, A.R., Zou, D., Risebrough, N., Buckstein, R., Kim, T. & Brereton, N. (2014) Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes. Current Oncology (Toronto, Ont.), 21, e29–40.
23. Marcucci, G., Maharry, K., Radmacher, M.D., Mrozek, K., Vukosavljevic, T., Paschka, P., Whitman, S.P., Langer, C., Baldus, C.D., Liu, C.G., Ruppert, A.S., Powell, B.L., Carroll, A.J., Caligiuri, M.A., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 26, 5078–87.
24. Marcucci, G., Haferlach, T. & Döhner, H. (2011) Molecular Genetics of Adult Acute Myeloid Leukemia: prognostic and Therapeutic Implications. Journal of Clinical Oncology, 29, 475–486.
25. Mardis, E.R. (2011) A decade's perspective on DNA sequencing technology. Nature, 470, 198–203.
26. Mrozek, K., Marcucci, G., Paschka, P., Whitman, S.P. & Bloomfield, C.D. (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, 109, 431–48.
27. NCCN. 2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Acute Myeloid Leukemia. Version 1.2015 Available at http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
28. de Oliveira, C., Bremner, K.E., Pataky, R., Gunraj, N., Chan, K., Peacock, S. & Krahn, M.D. (2013) Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open, 1, E1–8.
29. Ossenkoppele, G. & Löwenberg, B. (2015) How I treat the older patient with acute myeloid leukemia. Blood, 125, 767–774.
30. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28, 3636–43.
31. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O. & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New England Journal of Medicine, 366, 1079–89.
32. Port, M., Bottcher, M., Thol, F., Ganser, A., Schlenk, R., Wasem, J., Neumann, A. & Pouryamout, L. (2014) Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Annals of Hematology, 93, 1279–86.
33. Ravandi, F., Alattar, M.L., Grunwald, M.R., Rudek, M.A., Rajkhowa, T., Richie, M.A., Pierce, S., Daver, N., Garcia-Manero, G., Faderl, S., Nazha, A., Konopleva, M., Borthakur, G., Burger, J., Kadia, T., Dellasala, S., Andreeff, M., Cortes, J., Kantarjian, H. & Levis, M. (2013) Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 121, 4655–62.
34. Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A., Dohner, H. & GERMAN-AUSTRIAN ACUTE MYELOID LEUKEMIA STUDY, G., (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 358, 1909–18.
35. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. & Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733–9.
36. Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N.J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I.F., Fojo, T., Siderov, J., Williamson, S., Camporesi, S., McVie, J.G., Purushotham, A.D., Naredi, P., Eggermont, A., Brennan, M.F., Steinberg, M.L., de Ridder, M., McCloskey, S.A., Verellen, D., Roberts, T., Storme, G., Hicks, R.J., Ell, P.J., Hirsch, B.R., Carbone, D.P., Schulman, K.A., Catchpole, P., Taylor, D., Geissler, J., Brinker, N.G., Meltzer, D., Kerr, D. & Aapro, M. (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol, 12, 933–80.
37. Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M. & Ehninger, G. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107, 4011–20.
38. Wang, H.I., Aas, E., Howell, D., Roman, E., Patmore, R., Jack, A. & Smith, A. (2014) Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model. Value Health, 17, 205–14.
39. Wetterstrand, K. A. 2015. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at www.genome.gov/sequencingcosts.